Quick Links

Physicians' Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Physicians' Education Resource®, LLC, designates this enduring material for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.


PER Pulse™ Recaps
for Rapid Summaries and Commentaries™: Update from Chicago: Advances in Lung Cancer focus on next-generation ALK tyrosine kinases, new classes of oncogenic drivers, including BRAF V600E mutations and MET exon 14 alterations, and investigation of combination immunotherapy in the first-line setting in patients with non-small-cell lung cancer.

Acknowledgment of Commercial Support

This activity is supported by educational grants from Novartis Pharmaceuticals Corporation.

Rapid Summaries and Commentaries™: Update From Chicago: Advances in the Treatment of Lung Cancers

Release Date: June 14, 2016
Expiration Date: June 14, 2017
Media: Internet - based

Activity Overview

This activity is designed to update physicians on recent data sets presented at the Chicago meeting, so that practitioners, who manage patients with lung cancer, can assess and consider how these findings apply to their clinical practices. Some key trial information was presented at the meeting on targeted agents in patients with actionable molecular markers, emerging biomarkers, how recent findings may impact decision making when sequencing therapies, and early-phase clinical trial results concerning the use of front-line immunotherapy in non-small cell lung cancer. 

CME Activity Table of Contents

  • Phase 2 Trial of Brigatinib in Patients With ALK-Positive Non-Small Cell Lung Cancer Progressing on Crizotinib (ALTA)
  • Phase 3 Trial of Alectinib Versus Crizotinib in Japanese Patients With ALK-Positive, ALK Inhibitor-Naïve, Non-Small Cell Lung Cancer
  • Phase 2 Trial of Dabrafenib/Trametinib in Patients With Previously Treated, BRAFV600E-Mutated Non-Small Cell Lung Cancer
  • Crizotinib in Patients With Non-Small Cell Lung Cancer and MET Exon 14 Alterations: Report From a Cohort in the PROFILE 1001 Study[
  • Phase 1 Trial of Nivolumab/Ipilimumab as First-Line Therapy in Patients With Advanced Non-Small Cell Lung Cancer

Instructions For This Activity & Receiving Credit

  • You will need to login to participate in the activity.
  • Each presentation may contain an interactive question(s). You may move forward through the presentation; however, you may not go back to change answers or review videos/content until you finish the presentation.
  • At the end of the activity, "educational content/video" will be available for your reference.
  • In order to receive a CME certificate, participants must complete the activity.
  • Complete the posttest and pass with a score of 70% or higher, complete the evaluation and then click on request for credit. Participants may immediately download a CME certificate upon completion of these steps.

Target Audience

This educational activity is directed toward medical oncologists and fellows who treat patients with lung cancers. Surgical oncologists, radiation oncologists, pulmonologists, nurse practitioners, nurses, physician assistants, pharmacists, researchers, and other healthcare professionals interested in the treatment of lung may also participate.

Educational Objectives

At the conclusion of this activity, you should be better prepared to:
  • Discuss the design and endpoints of noteworthy clinical trials evaluating novel strategies for the management of lung cancer
  • Evaluate recent clinical trial findings on novel compounds and strategies for patients with advanced non-small cell lung cancer (NSCLC)
  • Explain the clinical implications of recent trial findings in the context of evolving treatment paradigms in the field of advanced NSCLC
  • Apply practice-changing information on immunotherapeutic and targeted approaches to care for patients with advanced forms of lung cancer

Faculty, Staff, and Planners' Disclosures


David R. Gandara, MD
Professor of Medicine
Division of Hematology/Oncology
Director, Thoracic Oncology Program
Senior Advisor to the Director
UC Davis Comprehensive Cancer Center
Sacramento, CA
Disclosure: Research Grants: AstraZeneca/Medi, Bristol-Myers Squibb, Clovis, Genentech, Johnson & Johnson, Lilly, Merck, Novartis; Consultant: AstraZeneca, Boehringer-Ingelheim, Celgene, Clovis, Genentech, Guardant Health, Lilly, Merck, Novartis, Pfizer, Synta.

Mark G. Kris, MD
Attending Physician, Thoracic Oncology
William and Joy Ruane Chair in Thoracic Oncology
Lead Physician, IBM Watson Collaboration
Memorial Sloan Kettering Cancer Center
Professor of Medicine, Weill Cornell Medicine
New York, NY
Disclosure: Grant/Research Support: Genentech, Roche; Consultant: Genentech, Roche, Ariad Pharmaceuticals

The following individuals have no relevant financial relationships with commercial interests:
The staff of PER®, LLC.

Disclosure Policy and Resolution of Conflicts of Interest (COI)

It is the policy of Physicians' Education Resource®, LLC, (PER®) to ensure fair balance, independence, objectivity, and scientific rigor in all of our CME activities. In accordance with ACCME guidelines, PER® requires everyone who is in a position to control the content of an educational activity, including spouses/partners, to disclose all relevant financial relationships with any commercial interest to participants as a part of the activity planning process. PER® has implemented mechanisms to identify and resolve all conflicts of interest prior to release of this activity.

Off-Label Disclosure and Disclaimer

This CME activity may or may not discuss investigational, unapproved, or off-label uses of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME activity is for continuing medical education purposes only, and is not meant to substitute for the independent medical judgment of a physician or nurse relative to diagnostic, treatment, or management options for a specific patient's medical condition.

The opinions expressed in the content are solely those of the individual faculty members, and do not reflect those of Physicians' Education Resource®, LLC, or any of the companies that provided commercial support for this activity.

Hardware And Software Requirements

Supported Browsers
Internet Explorer v.7 or greater (for Windows) | Mozilla Firefox v.2 or greater (for Windows, Mac, Linux)

Minimum System Requirements (Windows)
  • A Pentium-based PC or compatible computer
  • At least 64MB of RAM
  • Windows 95/98/NT/ME/2000/XP/Vista system software
  • Screen resolution of 1024 x 786 or larger recommended
  • PDF Reader: Adobe Reader 5.0 or higher, Foxit Reader 2.0 or likewise
Minimum System Requirements (Mac OS)
  • A PowerPC processor-based Macintosh computer
  • At least 64MB of RAM
  • Mac OS 7.5 or later
  • Screen resolution of 1024 x 786 or larger recommended
  • PDF Reader: Adobe Reader 5.0 or higher, Foxit Reader 2.0 or likewise

Become a Member

Forgot Password?
Calendar of Events
Filter By